Mar 18, 01:35 PM

Sofinnova Partners Raises €165M for Largest European Biotech Fund, Part of €1.2 Billion Strategy, Launching Three Startups

Sofinnova Partners has successfully closed its Biovelocita II fund, raising €165 million, making it the largest pan-European biotech acceleration fund. The fund exceeded its initial target and is backed by major pharmaceutical companies including Amgen, Bristol Myers Squibb, and Pfizer Ventures. The capital will be used to support early-stage biotech startups across Europe, aiming to foster innovation in the life sciences sector. This initiative is part of a broader €1.2 billion investment strategy disclosed by Sofinnova earlier this month, which includes three new startups launched under the Biovelocita II program. The fund aims to transform healthcare through the development of academic spinouts and innovative biotech solutions.

#Sofinnova Partners #Biovelocita II #Amgen #Bristol Myers Squibb #Pfizer Ventures #Europe #Sofinnova

Written with ChatGPT (GPT-4o mini).

Sources

Additional media

Image #1 for story sofinnova-partners-raises-eur165m-largest-european-biotech-fund-part-eur1-2-83db051f

Image #2 for story sofinnova-partners-raises-eur165m-largest-european-biotech-fund-part-eur1-2-83db051f

Sofinnova Partners Raises €165M for Largest European Biotech Fund, Part of €1.2 Billion Strategy, Launching Three Startups

Sources

Additional media

Similar Stories